• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

男性糖尿病患者中常见高风险与有利风险前列腺癌的死亡原因。

Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.

机构信息

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA.

出版信息

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1329-37. doi: 10.1016/j.ijrobp.2009.06.051. Epub 2009 Oct 30.

DOI:10.1016/j.ijrobp.2009.06.051
PMID:19879061
Abstract

PURPOSE

To determine whether prevalent diabetes mellitus (pDM) affects the presentation, extent of radiotherapy, or prostate cancer (PCa)-specific mortality (PCSM) and whether PCa aggressiveness affects the risk of non-PCSM, DM-related mortality, and all-cause mortality in men with pDM.

METHODS

Between October 1997 and July 2907, 5,279 men treated at the Chicago Prostate Cancer Center with radiotherapy for PCa were included in the study. Logistic and competing risk regression analyses were performed to assess whether pDM was associated with high-grade PCa, less aggressive radiotherapy, and an increased risk of PCSM. Competing risks and Cox regression analyses were performed to assess whether PCa aggressiveness described by risk group in men with pDM was associated with the risk of non-PCSM, DM-related mortality, and all-cause mortality. Analyses were adjusted for predictors of high-grade PCa and factors that could affect treatment extent and mortality.

RESULTS

Men with pDM were more likely (adjusted hazard ratio [AHR], 1.9; 95% confidence interval [CI], 1.3-2.7; p = .002) to present with high-grade PCa but were not treated less aggressively (p = .33) and did not have an increased risk of PCSM (p = .58) compared to men without pDM. Among the men with pDM, high-risk PCa was associated with a greater risk of non-PCSM (AHR, 2.2; 95% CI, 1.1-4.5; p = .035), DM-related mortality (AHR, 5.2; 95% CI, 2.0-14.0; p = .001), and all-cause mortality (AHR, 2.4; 95% CI, 1.2-4.7; p = .01) compared to favorable-risk PCa.

CONCLUSION

Aggressive management of pDM is warranted in men with high-risk PCa.

摘要

目的

确定是否普遍存在的糖尿病(pDM)会影响表现、放疗范围或前列腺癌(PCa)特异性死亡率(PCSM),以及 PCa 的侵袭性是否会影响患有 pDM 的男性的非 PCaSM、DM 相关死亡率和全因死亡率的风险。

方法

1997 年 10 月至 2007 年 7 月期间,共有 5279 名在芝加哥前列腺癌中心接受放疗治疗 PCa 的男性患者被纳入研究。使用逻辑回归和竞争风险回归分析评估 pDM 是否与高级别 PCa、放疗范围不那么积极以及 PCSM 风险增加相关。使用竞争风险和 Cox 回归分析评估患有 pDM 的男性中按风险组描述的 PCa 侵袭性是否与非 PCaSM、DM 相关死亡率和全因死亡率的风险相关。分析调整了高级别 PCa 的预测因素和可能影响治疗范围和死亡率的因素。

结果

患有 pDM 的男性更有可能出现高级别 PCa(调整后的危险比 [AHR],1.9;95%置信区间 [CI],1.3-2.7;p =.002),但与没有 pDM 的男性相比,他们的放疗范围不那么积极(p =.33),并且没有增加 PCSM 的风险(p =.58)。在患有 pDM 的男性中,高危 PCa 与非 PCaSM(AHR,2.2;95% CI,1.1-4.5;p =.035)、DM 相关死亡率(AHR,5.2;95% CI,2.0-14.0;p =.001)和全因死亡率(AHR,2.4;95% CI,1.2-4.7;p =.01)的风险增加相关,而不是低危 PCa。

结论

患有高危 PCa 的男性需要积极管理 pDM。

相似文献

1
Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.男性糖尿病患者中常见高风险与有利风险前列腺癌的死亡原因。
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1329-37. doi: 10.1016/j.ijrobp.2009.06.051. Epub 2009 Oct 30.
2
Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.接受近距离放射治疗联合或不联合外部束放射治疗的中危前列腺癌老年男性患者前列腺癌特异性死亡率的预测因素。
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):147-52. doi: 10.1016/j.ijrobp.2009.04.085. Epub 2009 Sep 8.
3
Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.高危前列腺癌患者接受放疗时,联合雄激素阻断与单独使用黄体生成素释放激素激动剂的疗效比较。
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.
4
Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.高危前列腺癌老年健康男性的前列腺癌特异性死亡率与治疗范围。
Cancer. 2010 Jun 1;116(11):2590-5. doi: 10.1002/cncr.24974.
5
Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).在既定的格里森评分类别内年龄增长与前列腺癌特异性死亡率(PCSM)的风险。
BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.
6
Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.局限性、中危至高风险前列腺癌男性患者接受短程激素治疗或根治性前列腺切除术后的癌症特异性死亡率
Cancer. 2006 Dec 1;107(11):2597-603. doi: 10.1002/cncr.22279.
7
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.预测中高危疾病且伴有多种不利风险因素男性的前列腺癌死亡率。
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64. doi: 10.1016/j.ijrobp.2008.05.009. Epub 2008 Aug 7.
8
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.根治性前列腺切除术或外照射放疗后有1个或更多高危因素男性的前列腺癌特异性死亡率。
Cancer. 2007 Jul 1;110(1):56-61. doi: 10.1002/cncr.22737.
9
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.根治性前列腺切除术或放射治疗后前列腺癌特异性死亡率的预测因素。
J Clin Oncol. 2005 Oct 1;23(28):6992-8. doi: 10.1200/JCO.2005.01.2906.
10
Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.低风险或预后良好的中风险疾病患者中,阳性前列腺穿刺活检组织芯比例对前列腺癌特异性死亡率的影响。
J Clin Oncol. 2004 Sep 15;22(18):3726-32. doi: 10.1200/JCO.2004.01.164.

引用本文的文献

1
MnTE-2-PyP, a manganese porphyrin, reduces cytotoxicity caused by irradiation in a diabetic environment through the induction of endogenous antioxidant defenses.MnTE-2-PyP(一种锰卟啉)通过诱导内源性抗氧化防御来减少糖尿病环境中辐射引起的细胞毒性。
Redox Biol. 2020 Jul;34:101542. doi: 10.1016/j.redox.2020.101542. Epub 2020 Apr 21.
2
The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.一项基于人群的研究中,美国黑人和白人中糖尿病与肥胖症与前列腺癌侵袭性的关联。
Cancer Causes Control. 2016 Dec;27(12):1475-1485. doi: 10.1007/s10552-016-0828-0. Epub 2016 Nov 9.
3
Diabetes and mortality in patients with prostate cancer: a meta-analysis.
前列腺癌患者的糖尿病与死亡率:一项荟萃分析。
Springerplus. 2016 Sep 13;5(1):1548. doi: 10.1186/s40064-016-3233-y. eCollection 2016.
4
A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.代谢综合征与前列腺癌患者运动相关的临床效果评价。
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):323-332. doi: 10.1038/pcan.2016.25. Epub 2016 Jun 28.
5
Diabetes, Epstein-Barr virus and extranodal natural killer/T-cell lymphoma in India: Unravelling the plausible nexus.印度的糖尿病、爱泼斯坦-巴尔病毒与结外自然杀伤/T细胞淋巴瘤:探寻可能的关联
Indian J Med Paediatr Oncol. 2016 Jan-Mar;37(1):6-13. doi: 10.4103/0971-5851.177002.
6
Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions.前列腺癌的治疗与生存:有常见合并症男性患者的证据。
Med Care. 2014 Jun;52(6):482-9. doi: 10.1097/MLR.0000000000000113.
7
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer.将肥胖、糖尿病和代谢综合征与癌症联系起来的流行病学及分子机制。
Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S233-9. doi: 10.2337/dcS13-2001.
8
Diabetes and risk of cancer.糖尿病与癌症风险。
ISRN Oncol. 2013;2013:583786. doi: 10.1155/2013/583786. Epub 2013 Feb 7.
9
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.二甲双胍与前列腺癌:降低去势抵抗性疾病的发展和前列腺癌死亡率。
Eur Urol. 2013 Apr;63(4):709-16. doi: 10.1016/j.eururo.2012.12.004. Epub 2012 Dec 14.
10
Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer.前列腺癌患者接受外照射放疗、根治性前列腺切除术或近距离放射治疗后10年的胃肠道和泌尿生殖系统长期毒性。
Prostate Cancer. 2012;2012:853487. doi: 10.1155/2012/853487. Epub 2012 Apr 11.